The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
By K. Vermeulen, D. Van Bockstaele, Z. Berneman. Cell Proliferation, 2003
1,840 citations recorded by the source corpus.
Abstract. The cell cycle is controlled by numerous mechanisms ensuring correct cell division. This review will focus on these mechanisms, i.e. regulation of cyclin‐dependent kinases (CDK) by cyclins, CDK inhibitors and phosphorylating events. The quality checkpoints activated after DNA damage are also discussed. The complexity of the regulation of the cell cycle is also reflected in the different alterations leading to aberrant cell proliferation and development of cancer. Consequently, targeting the cell cycle in general and CDK in particular presents unique opportunities for drug discovery. This review provides an overview of deregulation of the cell cycle in cancer. Different families of known CDK inhibitors acting by ATP competition are also discussed. Currently, at least three compounds with CDK inhibitory activity (flavopiridol, UCN‐01, roscovitine) have entered clinical trials.
Subfields: Cell Biology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/9ea90fbb5586b8d1ea4b2120091a6b6e1180b4cf
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cell Biology
In Molecular Biology
In Oncology
Citations in the corpus
- Regulation of DNA repair throughout the cell cycle (2008, background): “CDKs regulate cell-cycle transitions by inducing degradation of cell-cycle inhibitory proteins ( Box 2 ) and are periodically activated by their regulatory cyclin subunits, which are differentially expressed during the different cell-cycle phase”
- Therapeutic delivery of miR-26a inhibits cancer cell proliferation and induces tumor-specific apoptosis (2009, neutral): “S checkpoint (Vermeulen et al., 2003).”